Search

Displaying results 1061 - 1070 of 10000 in total
  1. Drug

    Ipratropium

    go.drugbank.com/drugs/DB00332
    ApprovedInvestigational

    [A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol … Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.

    Mixtures: BERODUAL® HFA, BERODUAL® HFAProducts: A-TROFINSA, Aa-ipravent
  2. Drug

    Moclobemide

    go.drugbank.com/drugs/DB01171
    ApprovedInvestigational

    A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. … Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (

    Synonyms: 4-Chlor-N-(2-morpholinoethyl)benzamid, p-Chloro-N-(2-morpholinoethyl)benzamideCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A Inhibitors
  3. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    [A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. … [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: Ag-letrozole, Ag-letrozole Tablets
  4. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366

    Mixtures: EMAXIN BASLANGIC SETI, 7+7+7+7 ADET, EMAXIN BASLANGIC SETI, 7+7+7+7 ADETCategories: N-methyl-D-aspartate Receptor Antagonist, NMDA Receptor Antagonists
  5. Drug

    Methyl salicylate

    go.drugbank.com/drugs/DB09543
    ApprovedInvestigationalVet approved

    It forms a colorless to yellow or reddish liquid and exhibits a characteristic odor and taste of wintergreen. … It can be manufactured synthetically and it used as a fragrance, in foods, beverages, and liniments.

    Mixtures: Cho-A Point Plaster, Cho-A Point PlasterCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Bisacodyl

    go.drugbank.com/drugs/DB09020
    ApprovedInvestigational

    Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation. … [A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300]

    Mixtures: BEKUNIS 3 MG/5 MG KAPLI TABLET, 30 ADET, Dyrax-Q TabSynonyms: Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)
  7. Drug

    Iron sucrose

    go.drugbank.com/drugs/DB09146
    ApprovedInvestigational

    Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis

    Mixtures: Marnatal FInternational brands: Ferosoft S
  8. Drug

    Rosuvastatin

    go.drugbank.com/drugs/DB01098
    ApprovedInvestigational

    as well as the need for surgical revascularization or angioplasty following a heart attack. … [A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular

    Synonyms: (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acidMixtures: ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI, ROSUVINA LEGRAND® E 10/40
  9. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor AntagonistsProducts: TICLOPIDIN AL 250, TICLOPIDIN - CT 250MG FTA
  10. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    [A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. … Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide